SCHEMBL140343

SCHEMBL140343

CC(C)(C)C(=O)Nc1cc(Oc2cc(F)c(N(C(=O)C3(C(N)=O)CC3)c3ccc(F)cc3)cc2F)ccn1

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KDR P35968 12/20 0.47
MET P08581 6/20 0.47
NTRK1 P04629 1/20 0.47
TEK Q02763 1/20 0.47
NTRK3 Q16288 1/20 0.47
NTRK2 Q16620 1/20 0.47
GCK P35557 2/20 0.39
BRAF P15056 6/20 0.38
AXL P30530 1/20 0.36
MERTK Q12866 1/20 0.36
TGFBR1 P36897 1/20 0.35
ABL1 P00519 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL142813 0.94 KDR (0.46) KDRMETNTRK1TEKNTRK3
SCHEMBL138397 0.91 KDR (0.49) KDRMETNTRK1TEKNTRK3
SCHEMBL138413 0.89 MET (0.47) KDRMETNTRK1TEKNTRK3
SCHEMBL140476 0.89 MET (0.47) KDRMETNTRK1TEKNTRK3
SCHEMBL141722 0.89 MET (0.49) KDRMETNTRK1TEKNTRK3
SCHEMBL140475 0.89 MET (0.47) KDRMETNTRK1TEKNTRK3
SCHEMBL139907 0.88 KDR (0.62) KDRMETNTRK1TEKNTRK3
SCHEMBL143306 0.88 MET (0.46) KDRMETNTRK1TEKNTRK3
SCHEMBL138270 0.88 MET (0.46) KDRMETNTRK1TEKNTRK3
SCHEMBL139989 0.87 KDR (0.45) KDRMETNTRK1TEKNTRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120252849-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHAMACEUTICALS, LLC (US) 2012-10-04 US claimed
US-20120058985-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-03-08 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252849-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 KDR 3640/4885MET 2169/4885NTRK1 3749/4885
US-20120058985-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 KDR 3640/4885MET 2169/4885NTRK1 3749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.